WS PARTNERS / FUND NEWS
AtonRâ Bionics lifts genomics and diagnostics to 49% of portfolio as top holdings change
Fund changes · Published 2 November 2026
AtonRâ Partners said the Bionics strategy’s recovery since the October 2023 trough has been driven by new holdings, with Natera Inc, Twist Bioscience and Illumina now the top three positions and none held three years ago.
Genomics and diagnostics now make up 49% of the Bionics portfolio, three times the average peer exposure, and the strategy is up 73% since the October 2023 trough versus 21% for the U.S. Medical Devices ETF (IHI). AtonRâ Partners said the Bionics NAV is back to July 2023 levels and remains 40% below its 2021 high.
Source: AtonRâ Partners.
Source statements are attributed; this is not investment advice.